[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2007000103A - 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización - Google Patents

2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización

Info

Publication number
DOP2007000103A
DOP2007000103A DO2007000103A DO2007000103A DOP2007000103A DO P2007000103 A DOP2007000103 A DO P2007000103A DO 2007000103 A DO2007000103 A DO 2007000103A DO 2007000103 A DO2007000103 A DO 2007000103A DO P2007000103 A DOP2007000103 A DO P2007000103A
Authority
DO
Dominican Republic
Prior art keywords
preparation
compositions
trihidroxi
benzotiazepinas
alquilamida
Prior art date
Application number
DO2007000103A
Other languages
English (en)
Inventor
Alain Commercon
Yannick Benedetti
Frederico Nardi
Jidong Zhang
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2007000103A publication Critical patent/DOP2007000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

2-Alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización. La presente invención se refiere principalmente a 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, las composiciones que las contienen y su utilización como medicamento, principalmente como agentes anticancerígenos.
DO2007000103A 2006-05-24 2007-05-24 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización DOP2007000103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0604735A FR2901555A1 (fr) 2006-05-24 2006-05-24 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur preparation, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
DOP2007000103A true DOP2007000103A (es) 2007-11-15

Family

ID=37496965

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2007000103A DOP2007000103A (es) 2006-05-24 2007-05-24 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización

Country Status (31)

Country Link
US (1) US7960373B2 (es)
EP (1) EP2029596B1 (es)
JP (1) JP2009537615A (es)
KR (1) KR20090010214A (es)
CN (1) CN101454278A (es)
AR (1) AR061104A1 (es)
AT (1) ATE458738T1 (es)
AU (1) AU2007253197A1 (es)
BR (1) BRPI0711892A2 (es)
CA (1) CA2652361A1 (es)
CR (1) CR10428A (es)
CY (1) CY1110089T1 (es)
DE (1) DE602007004982D1 (es)
DK (1) DK2029596T3 (es)
DO (1) DOP2007000103A (es)
EA (1) EA200870566A1 (es)
EC (1) ECSP088897A (es)
ES (1) ES2341589T3 (es)
FR (1) FR2901555A1 (es)
GT (1) GT200800254A (es)
MA (1) MA30560B1 (es)
MX (1) MX2008014957A (es)
NO (1) NO20085189L (es)
PE (1) PE20080258A1 (es)
PL (1) PL2029596T3 (es)
PT (1) PT2029596E (es)
SI (1) SI2029596T1 (es)
TN (1) TNSN08442A1 (es)
TW (1) TW200812990A (es)
UY (1) UY30366A1 (es)
WO (1) WO2007135294A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692522A (en) 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6239127B1 (en) * 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
CO5140099A1 (es) 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
PT1282604E (pt) * 2000-05-11 2008-04-11 Novartis Ag Carbonatos e éteres caprolactâmicos substituídos e seu uso como agentes anti-tumorais
AU2002217020A1 (en) 2000-11-14 2002-05-27 Novartis Ag Method for screening anti-proliferative compounds and inhibiting tumor growth
US6545148B2 (en) 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
MXPA06000975A (es) * 2003-07-25 2006-04-11 Novartis Ag Lactams sustituidos y su uso como agentes anti-cancer.
US7153846B2 (en) 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2878528B1 (fr) * 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Also Published As

Publication number Publication date
US7960373B2 (en) 2011-06-14
MX2008014957A (es) 2008-12-10
DE602007004982D1 (de) 2010-04-08
EP2029596B1 (fr) 2010-02-24
JP2009537615A (ja) 2009-10-29
MA30560B1 (fr) 2009-07-01
NO20085189L (no) 2009-02-11
FR2901555A1 (fr) 2007-11-30
ECSP088897A (es) 2008-12-30
TNSN08442A1 (en) 2010-04-14
DK2029596T3 (da) 2010-06-14
WO2007135294A2 (fr) 2007-11-29
PL2029596T3 (pl) 2010-07-30
CA2652361A1 (fr) 2007-11-29
EP2029596A2 (fr) 2009-03-04
ES2341589T3 (es) 2010-06-22
TW200812990A (en) 2008-03-16
ATE458738T1 (de) 2010-03-15
SI2029596T1 (sl) 2010-07-30
CR10428A (es) 2008-12-01
AR061104A1 (es) 2008-08-06
KR20090010214A (ko) 2009-01-29
PE20080258A1 (es) 2008-05-12
BRPI0711892A2 (pt) 2012-01-10
CY1110089T1 (el) 2015-01-14
AU2007253197A1 (en) 2007-11-29
EA200870566A1 (ru) 2009-04-28
WO2007135294A3 (fr) 2008-01-17
PT2029596E (pt) 2010-05-28
US20090093459A1 (en) 2009-04-09
UY30366A1 (es) 2008-01-02
GT200800254A (es) 2009-03-13
CN101454278A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
HN2009000784A (es) Dihidropirazolonas sustituidas
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR10247A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
SV2006002384A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
UY29248A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY29371A1 (es) Pirroles sustituídos, composiciones que los contienen, proceso de fabricación y utilización
ECSP109874A (es) Nuevos compuestos 892
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
ECSP088893A (es) 2-alcoxi-3, 4,5-trihidroxi-alquilamida-benzazepinas, su preparación, composiciones que las contienen y utilización
ECSP088899A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparación, composiciones que las contienen y utilización
ECSP088897A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparación, composiciones que las contienen y utilización
CR9115A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
UY29501A1 (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricación y utilización
UY29235A1 (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparación, composiciones que las contienen y utilización
DOP2005000246A (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
GT200500165A (es) Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6